TNBC subtypes |
|||||||
Molecular features |
Related paths |
BL1 |
BL2 |
M |
МSL |
LAR |
IM |
Communication and cell motility |
Rho/Rac, GTP-ase, Src, VEGF |
||||||
Self-renewal and differentiation of CSC |
ABCAB, PROCR, ENG, Wnt/β-catenin, Hedgehog |
||||||
Cell growth and metabolism |
IGF1, mTORC1/2; EIF4G, S6-kinase |
||||||
Cell growth and metabolism |
EGFR |
||||||
Cell cycle components, DNA replication |
Cyclins, PARP |
||||||
DNA Damage Repair |
BRCA1/2 |
||||||
Cell growth and death |
p53 |
||||||
Cell survival |
PI3K, AkT |
||||||
Immune cell signaling |
|||||||
Sensitivity to therapy |
Active ingredients |
BL1 |
BL2 |
M |
МSL |
LAR |
IM |
Src inhibitors |
Dasatinib |
||||||
PARP inhibitors |
Veliparib, Olaparib |
||||||
AR inhibitors |
Bicalutamide |
||||||
PI3K inhibitors |
NVP-BEZ235 |
||||||
EGFR inhibitors |
Matuzumab |
||||||
Wnt inhibitors |
WntC59 |
||||||
mTOR inhibitors |
Everolimus, Rapamycin |
||||||
Replication inhibitors |
Cisplatin |
||||||
Microtubule stabilizers |
Ixabepilone, Paclitaxel |
||||||
Angiogenesis inhibitors |
Bevacuzimab |
||||||
T cell activators |
Ipilimumab, Pembrolizumab |
||||||
Notation: – high relations; – moderate relations; – low relations; – effectively |
|||||||